This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
OVERVIEW OF ACTIVITY
Taken together, it is estimated that approximately 86,520 new non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cases were identified in the United States in the year 2014, and 23,590 individuals died from these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, comprising more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.
These proceedings from a CME symposium during the 56th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of various forms of NHL. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for NHL.
LEARNING OBJECTIVES
- Appraise recent data on therapeutic advances and changing practice standards in the non-Hodgkin lymphomas, including chronic lymphocytic leukemia (CLL), and integrate this information, as appropriate, into current clinical care.
- Develop an algorithm for the risk-stratified induction treatment of follicular lymphoma, diffuse large B-cell lymphoma and mantle-cell lymphoma.
- Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the addition of recently FDA-endorsed options for these patients.
- Appreciate the recent FDA approvals of novel targeted agents indicated for the treatment of newly diagnosed and relapsed/refractory CLL, and discern how these treatments can be appropriately integrated into clinical practice.
- Compare and contrast completed and ongoing clinical trials evaluating novel investigational approaches for B-cell lymphomas and CLL, and use this information to refer appropriate patients for study participation and/or available expanded access programs.
- Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects.
ACCREDITATION STATEMENT
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Stephen M Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota
Research Funding: Bristol-Myers Squibb Company, Celldex Therapeutics.
Brad S Kahl, MD
Skoronski Chair of Lymphoma Research
Associate Professor
University of Wisconsin School of
Medicine and Public Health
Associate Director for Clinical Research
UW Carbone Cancer Center
Madison, Wisconsin
Advisory Committee: Celgene Corporation, Genentech BioOncology, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Genentech BioOncology, Roche Laboratories Inc.
John P Leonard, MD
Richard T Silver Distinguished
Professor of Hematology
and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York
Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Spectrum Pharmaceuticals Inc.
Gilles A Salles, MD, PhD
Professor of Medicine
Université Claude Bernard
Head of the Hematology
Department Hospices Civils
Lyon, France
Advisory Committee: Celgene Corporation, Gilead Sciences Inc, Janssen Pharmaceuticals Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Mundipharma International Limited, Roche Laboratories Inc; Other Remunerated Activities: Amgen Inc, Roche Laboratories Inc.
Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska
Contracted Research: Allos Therapeutics, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Spectrum Pharmaceuticals Inc, US Biotest Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals, an Amgen subsidiary and Takeda Oncology.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: March 2015
Expiration date: March 2016